Theodore Kim, DO
Hematology & Oncology · Anchorage, AKNPI 1952325359
Payments from drug & device makers
Across 150 payments — averaging $9152.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.3M
- Genentech, Inc.$28K
- Pfizer$15K
- Genentech USA, Inc.$287
- Novartis$256
- Incyte Corporation$151
- plus $1K from 34 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $1,327,428 |
| Genentech, Inc. | 1 | $28,000 |
| Pfizer | 42 | $15,364 |
| Genentech USA, Inc. | 14 | $287 |
| Novartis | 11 | $256 |
| Incyte Corporation | 5 | $151 |
| Johnson & Johnson | 2 | $122 |
| AstraZeneca(2 entities) | 4 | $116 |
| AbbVie | 3 | $87 |
| E.r. Squibb & Sons, L.L.C. | 4 | $86 |
| Gilead | 4 | $80 |
| Bayer | 2 | $67 |
| Astellas Pharma US Inc | 2 | $62 |
| GSK | 3 | $60 |
| Bristol Myers Squibb | 3 | $54 |
| Puma Biotechnology, Inc. | 2 | $48 |
| Acrotech Biopharma Inc. | 2 | $45 |
| Amgen | 2 | $44 |
| Exelixis Inc. | 2 | $38 |
| EMD Serono, Inc. | 1 | $37 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Stemline Therapeutics Inc. | 1 | $31 |
| Tersera Therapeutics LLC | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| Boehringer Ingelheim | 1 | $27 |
| Springworks Therapeutics, Inc. | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $26 |
| Beone Medicines USA, Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Array Biopharma Inc | 2 | $23 |
| Mirati Therapeutics, Inc. | 1 | $22 |
| Genmab U.S., Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Seagen Inc. | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Sanofi | 1 | $15 |
How this compares
Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Anchorage
- Steven LiuAnchorage$6.9M
- Max RabinowitzAnchorage$14K
- Mary KlixAnchorage$13K
- Mary StewartAnchorage$9K
- Kendal WebbAnchorage$8K
- Natalie WallaceAnchorage$8K
- Shannon SmileyAnchorage$6K
- Charles BuessAnchorage$5K
- Anusiyanthan MariampillaiAnchorage$4K
- Ellen ChirichellaAnchorage$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.